Clinical Trials
220 trialsCAN3001
Janssen Research & Development, LLC
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
PRODIGY
University of Utah
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
waveLINE-003
Merck Sharp & Dohme LLC
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
REBEL
University of Utah
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
CaDAnCe-101
BeOne Medicines
GlofitReal
Hoffmann-La Roche
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
ACRUE
AstraZeneca
ALPHA3
Allogene Therapeutics
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
MK-9999-01A
Merck Sharp & Dohme LLC
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
MK-2140-010
Merck Sharp & Dohme LLC
MK-2140-011
Merck Sharp & Dohme LLC
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Abramson Cancer Center at Penn Medicine
Pola-ZRCHP
The First Affiliated Hospital with Nanjing Medical University
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Huazhong University of Science and Technology
OLYMPIA-3
Regeneron Pharmaceuticals
GLOHRT-01
Huazhong University of Science and Technology
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Ruijin Hospital
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
University of Texas Southwestern Medical Center
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis
REVERSE_2021
Azienda USL Reggio Emilia - IRCCS
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Bio-CAR-T BS Study
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
AstraZeneca
DALY 2-EU
Miltenyi Biomedicine GmbH
GRAIL
University Health Network, Toronto
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
OHSU Knight Cancer Institute
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center